top of page
  • Patient Education

Patient Education: Selinexor (Xpovio) - XPO1 inhibitor

Patient Education: Selinexor (Xpovio) - XPO1 inhibitor

Selinexor (Xpovio) - XPO1 inhibitor

Selinexor (Xpovio)

NIH National cancer institute - site info

This page contains brief information and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s): Xpovio

FDA Approved: Yes

Learn more:


MedlinePlus Information

A lay language summary of important information about this drug that may include the following:

warnings about this drug,

what this drug is used for and how it is used,

what you should tell your doctor before using this drug,

what you should know about this drug before using it,

other drugs that may interact with this drug, and

possible side effects.

Learn more:


Information on Xpovio website



Understanding Selinexor (Xpovio)

Download Booklet here

IMF Understanding Series

IMF Resource Library

Current FDA-Approved Medications for Multiple Myeloma Treatment



All About Xpovio (Selinexor)

Watch Video on YouTube

HealthTree University for Multiple Myeloma Lectures

Health Tree University Myeloma Videos



Standard Treatments - Selinexor (Xpovio)

MMRF Education Programs

MMRF Videos


References XPOVIO- selinexor tablet, film coated:

FDA Label Prescribing Information (Revised 08/2021)

Prescribing Information | XPOVIO

label (

Medication Guide

Drug Label Information at DAILYMED - NIH-National Library of Medicine

DailyMed - XPOVIO- selinexor tablet, film coated

Other Resources

Downloadable Resources


- Multiple Myeloma Patient Education & Information on ongoing Multiple Myeloma Clinical Trials -

Posts Archive
bottom of page